.png)
.png)
|
According to Celltrion, Zymfentra recorded its highest monthly prescription volume ever in January, rising more than threefold (up 213%) year-on-year. The January prescription volume not only exceeded that of the same month last year but also surpassed the entire prescription total for the first quarter of last year, suggesting that adoption of Zymfentra is accelerating rapidly across U.S. medical institutions.
The product’s strong growth is also reflected in actual market demand indicators. Celltrion said that shipments of Zymfentra supplied to U.S. wholesalers and retailers in February increased more than 3.5 times year-on-year. Given that biologics have limited shelf lives and medical institutions typically place orders with wholesalers based on real patient prescription trends, shipment growth is viewed as a clear signal that patient demand is structurally expanding.
Industry observers attribute Zymfentra’s prescription momentum to Celltrion USA’s “3P strategy” targeting providers, payers, and patients, which includes tailored physician outreach, insurance coverage expansion, and integrated online and offline advertising.
First, direct engagement with specialists (providers) appears to have played a key role. Since Zymfentra’s launch in March 2024, Celltrion has actively communicated with autoimmune disease specialists across the United States. Chairman Seo Jung-jin and other executives, along with the U.S. sales team, have met directly with key physicians to explain the clinical value and therapeutic advantages of Zymfentra.
Such physician-focused communication has helped improve understanding of the product’s differentiated therapeutic benefits and is believed to have translated into increased prescriptions and growing trust in the market. As a result, Zymfentra has maintained steady quarterly prescription growth since launch, gradually establishing its presence in the U.S. autoimmune disease treatment market.
Another major driver has been broad insurance coverage. Celltrion has secured formulary listings with multiple large PBMs and insurers, including the three major pharmacy benefit managers (PBMs) in the United States, achieving coverage for more than 90% of the insured population.
Coverage continues to expand. In January, Zymfentra was added as a preferred drug on the formulary of Evernorth Health Services, a healthcare services company under the Cigna Group, further improving patient access. Expanded reimbursement coverage reduces out-of-pocket costs for patients while increasing physicians’ willingness to prescribe the drug, laying a foundation for accelerated prescription growth.
Celltrion has also strengthened patient-focused marketing efforts. The company’s U.S. subsidiary has conducted media campaigns through platforms such as YouTube and television, alongside promotional activities in medical institutions targeting both physicians and patients. This dual-track strategy has increased brand awareness and prescription preference, ultimately translating into higher prescription volumes.
Based on these market dynamics, Celltrion expects Zymfentra’s prescription growth and sales momentum to accelerate further. Structural growth factors—including its clinically validated therapeutic value, the ability to maintain high pharmacokinetic(PK) levels when switching from intravenous infliximab, making it suitable for maintenance therapy, and significantly improved patient convenience—are expected to support continued market share expansion in the U.S. autoimmune disease treatment market.
A Celltrion official said, “With Zymfentra prescriptions increasing more than threefold year-on-year in January and February shipment data confirming that this growth is supported by real hospital demand, the effectiveness of our 3P strategy targeting physicians, insurers, and patients is becoming evident. We will continue to strengthen sales and marketing activities to further expand prescriptions and sustain strong revenue growth.”
